Lantheus calls time on me-too Pluvicto
Final survival analysis draws a blank, and Lantheus throws in the towel.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Moderna returns to oncology
Three off-the-shelf mRNA therapies join intismeran autogene.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
